文献速递白血病

NOPHO ALL2008方案治疗1-45岁急性淋巴细胞白血病患者的结果

Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2017-08-18

北欧和波罗的海中心于2008年7月至2014年12月按NOPHO ALL2008方案(无颅脑照射)连续治疗1509例1-45岁费城染色体阴性急性淋巴细胞白血病患者,中位随访4.6年。5年无事件生存率1-9岁组为89±1%、10-17岁组为80±3%、18-45岁组为74±4%,仅非高危组差异显著。除血栓、胰腺炎和骨坏死外,19种特定毒性的风险未因年龄大于10岁而增加。

要点

  • 1-9岁、10-17岁、18-45岁组5年无事件生存率分别为89±1%、80±3%、74±4%。
  • 高龄组更高危ALL特征更常见:T-ALL、KMT2A重排及B系第29天残留白血病更高。
  • 除血栓、胰腺炎和骨坏死外,19种特定毒性风险未因年龄大于10岁而增加。

核心结论

  • 以儿童方案为基础的NOPHO ALL2008方案对年轻成人可耐受且有效,尽管其高危特征频率更高。

研究设计与样本

  • 北欧和波罗的海中心于2008年7月至2014年12月按NOPHO ALL2008方案(无颅脑照射)连续治疗1509例1-45岁费城染色体阴性急性淋巴细胞白血病患者。
  • 患者按年龄分为1-9岁组1022例(A)、10-17岁组266例(B)、18-45岁组221例(C)。

主要发现

  • 诱导期16例死亡(其中成人3例),其余患者经诱导或1-3个强化 blocks 后均达缓解。
  • 后续45例死亡(其中成人12例),122例复发(其中成人32例),中位至复发时间1.6年,13例发生第二恶性肿瘤(无成人)。
  • 中位随访时间4.6年,5年无事件生存率A组89±1%、B组80±3%、C组74±4%,仅非高危组差异显著。
  • 高龄组更高危ALL更常见:T-ALL比例A/B/C组分别为9%/25%/32%(P<0.001),KMT2A重排分别为3%/5%/6%(P<0.001),B系第29天残留白血病更高(P<0.001),T-ALL无差异(P=0.53)。
  • 除血栓、胰腺炎和骨坏死外,19种特定毒性的风险未因年龄大于10岁而增加。

临床怎么用

  • 原文结论认为以儿童方案为基础的NOPHO ALL2008方案对年轻成人可耐受且有效,尽管其高危特征频率更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients aged 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. Overall, 1022 patients were of age 1-9 years (A), 266 were 10-17 years (B) and 221 were 18-45 years (C). Sixteen patients (three adults) died during induction. All others achieved remission after induction or 1-3 intensive blocks. Subsequently, 45 patients (12 adults) died, 122 patients relapsed (32 adults) with a median time to relapse of 1.6 years and 13 (no adult) developed a second malignancy. Median follow-up time was 4.6 years. Among the three age groups, older patients more often had higher risk ALL due to T-ALL (32%/25%/9%, P<0.001), KMT2A rearrangements (6%/5%/3%, P<0.001) and higher day 29 residual leukemia for B-lineage (P<0.001), but not T-ALL (P=0.53). Event-free survival rates (pEFS5y) were 89±1% (A), 80±3% (B) and 74±4% (C) with significant differences only for non-high risk groups. Except for thrombosis, pancreatitis and osteonecrosis, the risk of 19 specified toxicities was not enhanced by age above 10 years. In conclusion, a pediatric-based protocol is tolerable and effective for young adults, despite their increased frequency of higher risk features.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2017. PMID: 28819280. doi:10.1038/leu.2017.265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。